Clinical Trials Browser

HER2-positive Breast Cancer × atezolizumab × Genitourinary × Clear all

NCT03650348 2024-04-22

PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Phase 1 Completed

BreastGastrointestinalGenitourinaryOther solid neoplasm

HER2-positive Breast Cancer